Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE30-07-2015
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSECode of Conduct of Fair Disclosure
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE about formulation and adoption of Codes under SEBI (Prohibition of Insider Trading) Regulations, 2015.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSEShareholding Pattern For June 30, 2015
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSEUpdates
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that the Company has received approval from the US FDA for the Abbreviated New Drug Application (ANDA) for Gemifloxacin Mesylate Tablets (320 mg) with 180 days of generic drug exclusivity.Updates
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that the Company has received approval from the US FDA for the Abbreviated New Drug Application (ANDA) for Rivastigmine Capsules in 1.5 mg, 3 mg, 4.5 mg, 6 mg and Felodipine Extended - Release Tablets in 2.5 mg, 5 mg, 10 mg.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSEChange in Directorate
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that Shri Sundaram Yuvaraj has vacated his office pursuant to Section 167(b) of the Companies Act 2013 from the Board of Orchid and Shri R. Kannan has been inducted into the Board of the Company as a Non-Executive, Independent director with effect from May 28, 2015.Financial Results & Results Press Release for March 31, 2015 (Audited)
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE about the Financial Results & a copy of Results Press Release for the period ended March 31, 2015.